EP 1351976 A2 20031015 - GPE ANALOGS
Title (en)
GPE ANALOGS
Title (de)
GPE ANALOGE
Title (fr)
ANALOGUES DE GPE
Publication
Application
Priority
- NZ 50653400 A 20000824
- US 0141883 W 20010824
Abstract (en)
[origin: WO0216408A2] The invention relates to GPE analogs, particularly GPE analogs capable of inducing an equivalent physiological effect to GPE within a patient. Such GPE analogs include peptides where the Gly of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Pro; where the Pro of Gly-Pro-Glu is replaced by any of Ala, Ser, Thr, or Gly; and where the Glu of Gly-Pro-Glu is replaced by any of Asn, Asp, or Gln. The GPE analogs of the invention have application in any method of therapy or porphylaxis in which GPE has application. These applications include the treatment of acute brain injury and neurodegenerative disease, including but not limited to injury or disease in the CNS. The GPE analogs will normally be administered as part of a pharmaceutical composition or preparation.
IPC 1-7
IPC 8 full level
A61P 25/00 (2006.01); C07K 5/083 (2006.01); C07K 5/093 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61P 25/00 (2017.12); C07K 5/0806 (2013.01); C07K 5/0819 (2013.01); A61K 38/00 (2013.01)
Citation (search report)
See references of WO 0216408A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0216408 A2 20020228; WO 0216408 A3 20030424; AU 8916001 A 20020304; EP 1351976 A2 20031015
DOCDB simple family (application)
US 0141883 W 20010824; AU 8916001 A 20010824; EP 01968959 A 20010824